Ultragenyx Pharmaceutical (RARE) — Potential Target $30 / 100%Ultragenyx Pharmaceutical, Inc.BATS:RAREdarksignalUltragenyx Pharmaceutical has been in a prolonged downtrend after reaching the $60 area, with the price forming a series of lower highs and lower lows. The latest sell-off has pushed RARE sharply lower and the stock is now trading around $14.75, close to an important support area. The $13–15 zone is the key area to watch. Price has recently reacted from this region after the sharp decline, which suggests that buyers may be starting to defend the lows. The first important confirmation would be a sustained move back above the $18–20 area. Reclaiming this zone would improve the short-term structure and could signal that the recent sell-off is losing momentum. If buyers regain control, the first intermediate resistance is around $21–22, followed by the $26–27 area. A successful break above $27 would strengthen the rebound structure and could open the way toward the $36–37 resistance zone. The main measured-move target is around $29.50–30. From the current price near $14.75, this represents a potential upside of roughly 100%. The target is based on the recent measured move from the $14.80 area and also sits near an important previous reaction zone. The bullish rebound scenario would be invalidated if RARE loses the $13 support area and forms a new lower low. Until then, the setup can be viewed as a potential high-risk rebound from major support rather than a confirmed long-term trend reversal. Because the stock is still in a broader downtrend, confirmation is important. A reclaim of $18–20 would provide the first meaningful sign of strength, while a break above $26–27 would provide stronger confirmation of the recovery scenario. Disclaimer: This analysis is for educational and informational purposes only and does not constitute financial or investment advice. Trading and investing involve risk. Always do your own research before making any investment decision.